Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Progress in pharmaceutical development presentation with improved pharmacokinetics: a new formulation for valproate.

P Genton1

  • 1Centre Saint Paul, Marseille, France. piergen@aol.com

Acta Neurologica Scandinavica. Supplementum
|December 20, 2005
PubMed
Summary

New sustained-release sodium valproate microspheres improve epilepsy treatment. This formulation enhances patient compliance and quality of life, offering greater dosing flexibility for diverse patient needs.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prognostic factors in epilepsy with eyelid myoclonia (Jeavons syndrome).

Revue neurologique·2023
Same author

Will MRI replace the EEG for the diagnosis of nonconvulsive status epilepticus, especially focal?

Revue neurologique·2021
Same author

Joseph Roger. 1918-2012.

Neurophysiologie clinique = Clinical neurophysiology·2014
Same author

Wicket spikes misinterpreted as focal abnormalities in idiopathic generalized epilepsy with prescription of carbamazepine leading to paradoxical aggravation.

Neurophysiologie clinique = Clinical neurophysiology·2009
Same author

[Epilepsy with absence status: A new syndrome of idiopathic generalized epilepsy].

Revue neurologique·2009
Same author

[Juvenile myoclonic epilepsy in a patient with history of infantile hemiplegia].

Revue neurologique·2008

Area of Science:

  • Neurology
  • Pharmacology
  • Drug Delivery Systems

Background:

  • Epilepsy management requires effective antiepileptic drugs, optimal dosing, and patient adherence for long-term success.
  • Patient quality of life and drug tolerability are increasingly recognized as critical factors in therapeutic outcomes.
  • Sustained-release antiepileptic drug formulations can stabilize serum levels, reduce dosing frequency, and improve compliance.

Purpose of the Study:

  • To evaluate a novel sustained-release formulation of sodium valproate designed to overcome limitations of existing treatments.
  • To assess the impact of this new formulation on patient compliance, satisfaction, and quality of life.
  • To determine the suitability of the new formulation for individualized dosing in special patient populations.

Main Methods:

Related Experiment Videos

  • Development of a new sustained-release sodium valproate formulation as tasteless microspheres.
  • Presentation of the formulation in stick packs for individualized dosing convenience.
  • Evaluation of patient compliance, satisfaction, and quality of life in epilepsy patients using the new formulation.

Main Results:

  • The new microsphere formulation offers tasteless administration, suitable for sprinkling on food.
  • Stick pack presentation facilitates individualized dosing, addressing limitations of fixed-dose tablets.
  • Improved patient compliance and satisfaction are anticipated due to enhanced convenience and flexibility.

Conclusions:

  • The novel sustained-release sodium valproate microspheres represent an advancement in epilepsy management.
  • This formulation enhances patient adherence and quality of life through improved tolerability and dosing flexibility.
  • It offers a practical solution for individualized antiepileptic therapy, particularly in pediatric, elderly, and dysphagic patients.